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BI: Barthel Index; BP: blood pressure; FAST: face, arm, speech, time; GTN: 
glyceryl trinitrate; ICH: intracerebral haemorrhage; IS: ischaemic stroke; mRS: 
modified Rankin scale; NIHSS: National Institutes of Health Stroke Scale  
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ABSTRACT 
 
Rationale Vascular nitric oxide levels are low in acute stroke and donors such as 
glyceryl trinitrate (GTN) have shown promise when administered very early after 
stroke. Potential mechanisms of action include augmentation of cerebral 
reperfusion, thrombolysis and thrombectomy, lowering blood pressure (BP), and 
cytoprotection. 
 
Aim To test the safety and efficacy of 4 days of transdermal GTN (5 mg/day) 
versus sham in patients with ultra-acute presumed stroke who are recruited by 
paramedics prior to hospital presentation. 
 
Sample size estimates The sample size of 850 patients will allow a shift in the 
modified Rankin Scale (mRS) with odds ratio 0.70 (GTN versus sham, ordinal 
logistic regression) to be detected with 90% power at 5% significance (2-sided). 
 
Design The Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke 
Trial-2 (RIGHT-2) is a multicentre UK prospective randomised sham-controlled 
outcome-blinded parallel-group trial in 850 patients with ultra-acute (<4 hours of 
onset) FAST-positive presumed stroke and systolic BP >120 mmHg who present 
to the ambulance service following a 999 emergency call. Data collection is 
performed via a secure internet site with real-time data validation.  
 
Study outcomes The primary outcome is the mRS measured centrally by 
telephone at 90 days and masked to treatment. Secondary outcomes include: 
BP, impairment, recurrence, dysphagia, neuroimaging markers of the acute 
lesion including vessel patency, discharge disposition, length of stay, death, 
cognition, quality of life and mood. Neuroimaging and serious adverse events are 
adjudicated blinded to treatment. 
 
Discussion RIGHT-2 has recruited more than 500 participants from 7 UK 
ambulance services.  
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Status: Trial is ongoing. 
Funding: British Heart Foundation 
Registration: ISRCTN26986053 
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INTRODUCTION AND RATIONALE 
 
Treatment options for patients with acute stroke are few and may be categorised 
as those with high efficacy and high or medium cost but of limited utility, such as 
intravenous thrombolysis, thrombectomy, and hemicraniectomy;(1-4) those with 
intermediate efficacy and very wide utility, specifically stroke unit care;(5) and 
those with limited efficacy but wide utility and low cost, e.g. aspirin.(6) There are 
no definitive drug treatments for patients with spontaneous intracerebral 
haemorrhage (ICH) although blood pressure (BP) lowering in the hyperacute 
period may be effective (7) and is recommended in guidelines.(8-10) Hence, 
there is an urgent need for affordable, widely available interventions that will 
improve outcome after either ischaemic or haemorrhagic stroke. 
 
Nitric oxide (NO) donors are candidate treatments for acute stroke.(11, 12) NO 
is a cerebral and systemic vasodilator, modulates vascular and neuronal function, 
and inhibits apoptosis. Preclinical stroke studies show that NO donors improve 
regional cerebral blood flow, and reduce stroke lesion size if administered 
rapidly.(13) Five small clinical studies of NO donors have been performed in 
acute stroke. Intravenous sodium nitroprusside reduced BP without altering 
cerebral blood flow, and exhibited antiplatelet effects,(14) thereby precluding its 
use in ICH. Four small trials of transdermal glyceryl trinitrate (GTN, nitroglycerin) 
found that it lowered peripheral and central BP, 24 hour BP, and pulse 
pressure.(15-18) GTN had no effect on middle cerebral artery blood flow 
velocity, cerebral blood flow (hence, no evidence of cerebral steal), intracranial 
pressure, or platelet activity (so it can be given in ICH).(15, 17) Further, GTN 
improved vascular compliance (reduced augmentation index) and had no 
apparent safety concerns.(15-18) In the last of these pilot studies (Rapid 
Intervention with Glyceryl trinitrate in Hypertensive stroke Trial, RIGHT), GTN 
was administered within 4 hours of stroke onset and significantly, albeit 
unexpectedly, improved functional outcome in just 41 patients.(18) The large 
Efficacy of Nitric Oxide in Stroke trial (ENOS, 4,011 patients recruited from 173 
sites in 23 countries) found that GTN was safe to administer but did not modify 
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outcome when given within 48 hours, except in the prespecified subgroup of 273 
patients randomised within 6 hours who had an improvement in functional 
outcome.(19, 20) 
 
Most trials in acute stroke have been delivered in hospital but a number of pilot 
studies have found that it is feasible to test new interventions and diagnostics 
before hospital in the community (pre-hospital) in small trials, including 
magnesium, insulin, brain scanning, perconditioning, and BP lowering.(18, 21-
28) Recently, the large FAST-Mag trial showed that it was feasible to deliver a 
large phase III trial in the pre-hospital setting, at least in the US emergency care 
system.(29) While paramedics are uniquely placed to deliver early treatments, 
their experience of participating in randomised controlled trials (RCTs) to 
evaluate interventions is limited, in part because pre-hospital research 
infrastructure is still in development and because the logistics of RCTs are more 
challenging in this environment.(30) 
 
On the basis of apparent positive effects of GTN on outcome in patients treated 
very early,(18-20) meta-analyses of these data (Figure 1),(31) and the apparent 
feasibility of performing large stroke trials in the pre-hospital ambulance 
environment,(29) the Rapid Intervention with Glyceryl trinitrate in Hypertensive 
stroke Trial-2 (RIGHT-2, ISRCTN26986053) is testing the safety and efficacy of 
transdermal GTN in patients with ultra-acute presumed ischaemic or 
haemorrhagic stroke who are recruited by paramedics, and the feasibility of 
performing a large prehospital stroke trial in the United Kingdom. We describe 
here the rationale, design and protocol for RIGHT-2. 
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OBJECTIVES 
 
The RIGHT-2 trial is testing two primary questions in patients with ultra-acute 
presumed stroke: 
1. What is the safety and efficacy of GTN, a nitric oxide donor, when 
administered within 4 hours of stroke onset? 
2. What is the feasibility of performing a multicentre stroke trial where 
randomisation and treatment is delivered by paramedics in the pre-hospital 
UK National Health Service ambulance service environment? 
 
A further two secondary questions ask: 
1. What are the mechanisms by which GTN might work if it shows efficacy in 
patients with ultra-acute stroke? These include potential effects on 
reperfusion, accelerated resolution of arterial clot, cytoprotection, facilitation 
and amplification of thrombolysis and other reperfusion strategies, 
ambulatory BP, and vascular compliance. 
2. Is GTN safe in patients who are found in hospital to have had a mimic rather 
than stroke or transient ischaemic attack (TIA)? 
 
 
METHODS 
 
Trial design 
RIGHT-2 is a UK-based multicentre prospective randomised sham-controlled 
outcome-blinded parallel-group trial. 
 
Ethics and regulatory approvals 
The study is run according to the principles of the Declaration of Helsinki and 
Good Clinical Practice. Study approvals have been obtained from: UK Medicines 
competent authority (MHRA 03057/0064/001-0001, date 1 March 2015; EudraCT 
2015-000115-40) and Research Ethics Committee (Nottingham 2, 15/EM/0055, 
date 24 Feb 2015), and local research & development/innovation departments in 
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each participating Ambulance Service and Hospital (e.g. Nottingham University 
Hospitals NHS Trust, date 8 Sept 2015). The trial was registered 
(ISRCTN26986053) and adopted by the National Institute for Health Research 
Clinical Research Network (date 26 Feb 2015). Trial funding from the British 
Heart Foundation followed external peer review (grant: CS/14/4/30972, awarded 
11 Sept 2014), started on 1 May 2015, and will last three years. The Nottingham 
Stroke Research Partnership Group (comprising stroke survivors and carers) 
support the study question, design and delivery plan. Management of personal 
data adheres to the UK Data Protection Act 1998. The overall flow of patients 
through the trial, and schedule of procedures and evaluations, are summarised in 
Figure 2 and Table 1, respectively. 
 
Patient population 
Study-trained paramedics consider all patients they attend in the context of an 
emergency telephone call (999) for ‘stroke’. The inclusion and exclusion criteria 
are deliberately limited in number to simplify enrolment in a time-limited 
emergency environment, and to minimise any possible increase in time at scene 
whilst doing trial-related procedures. Additionally, the criteria attempt to 
maximise the chances that a participating patient will have a stroke or TIA rather 
than a mimic, and to minimise recruitment of patients that are already severely 
dependent before their suspected stroke. No log of excluded patients is kept by 
either ambulance services or hospitals. Unlike in FAST-Mag,(29) doctors are not 
involved in recruitment or consent, with paramedics solely responsible for 
selection, consent and enrolment. 
 
Inclusion criteria 
• Patients presenting to paramedics in context of 999 ambulance call with 
suspected stroke. 
• Age 18 years or more (with no maximum age).  
• ‘Face Arm Speech Time’ (FAST) score 2 or 3. 
• Time <=4 hours from symptom onset. 
• Systolic BP >=120 mmHg.  
• Informed consent from patient, or proxy consent from a relative/paramedic. 
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• Paramedic is from a participating ambulance station and trained in RIGHT-2 
procedures, and will take patient to a participating hospital with 
comprehensive/primary stroke centre. 
 
Exclusion criteria 
• Patient at a Nursing Home. 
• Glucose (BM stix) <2.5 mmol/l. 
• Glasgow Coma Scale <8. 
• Witnessed seizure/fit at presentation.  
• Known life expectancy <6 months. 
• Known to have taken a phosphodiesterase-5 inhibitor, such as sildenafil, 
within 24 hours of randomisation. 
• Known sensitivity to Transiderm Nitro patch. 
• Known sensitivity to DuoDERM hydrocolloid dressing. 
• Known previous enrolment into RIGHT-2. 
 
If it becomes apparent at a later point that the participant did not have a stroke, 
they continue in the trial and are followed-up as per protocol. Patients already 
taking a nitrate such as glyceryl trinitrate may be recruited into the trial. 
 
A comparison of the inclusion/exclusion criteria with the Face Arm Speech and 
Time test, and modified Los Angeles Prehospital Stroke Screen (mLAPSS, as used 
in FAST-MAG) is given in Table 2. Overall, the RIGHT-2 inclusion/exclusion 
criteria lead to a similar population of patients being recruited to those identified 
by mLAPSS. 
 
Consent 
Consent or proxy consent is obtained at the stroke scene or in the ambulance; if 
patients lack capacity initially, then further consent or proxy consent is obtained 
at hospital. The algorithm for consent is shown in Figure 3 and comprises three 
stages: 
• At scene/in ambulance, with supervision by paramedic, in all patients, for: 
Ambulance activities; four days of GTN/sham administration; day 2 repeat 
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brain scan (for research purposes); assessment of primary and secondary 
outcomes at days 90 and 365 by telephone or mail; and access to the 
participant’s data (for trial purposes). Patient capacity is assessed using 
structured questions – see below.(27) Patients with capacity give written or 
witnessed oral consent to the paramedic otherwise proxy consent is obtained 
from a relative/carer/friend, or by the paramedic as witnessed by another 
person. 
• In hospital at any time, with supervision by research team (research 
nurse/coordinator/doctor), in patients who lacked capacity in the ambulance, 
for: Follow-up procedures in hospital. Patients with capacity (assessed as 
above) give written or witnessed oral consent to the research team member 
otherwise proxy consent is obtained from a relative/carer/friend. Patients who 
regain capacity will be re-consented for these procedures. 
• In hospital prior to additional research, with supervision by research team for: 
Additional research, including one or more of blood and genetic biomarkers, 
transcranial Doppler, pulse wave analysis, and/or ambulatory blood pressure 
monitoring. Patients with capacity (assessed as above) give written or 
witnessed oral consent to the research team member otherwise proxy 
consent is obtained from a relative/carer/friend. 
 
Brief assessment of capacity by the paramedic is performed in the ambulance by 
explaining to the patient that they have had a suspected stroke, their BP may 
need lowering, and that a patch will be applied that might lower their BP.(27) 
They are then asked what the suspected diagnosis is (‘stroke’), what might need 
to be done to their BP (‘lower’), and how this will be done (‘patch’). Lack of 
capacity is assumed if one or more answers are missing or incorrect, and is likely 
to reflect that the patient is semi-conscious, dysphasic or confused. 
 
This overall consent approach builds on processes used in the PIL-FAST and 
RIGHT pilot stroke ambulance trials.(18, 26-28) It is designed to reflect that 
stroke is a severe and often fatal or disabling condition; that the treatment has 
to be given very early (and ideally in the diamond half-hour or golden hour (32)) 
in view of the apparent time-dependency of GTN;(18, 20) that paramedics are 
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independent healthcare professionals who routinely have to consent patients for 
treatments with potential risks given for serious conditions (such as thrombolysis 
for myocardial infarction); and that many patients will have capacity (22% in 
RIGHT (18)) so that waiver of consent would be inappropriate.(33) 
 
Randomisation 
Patients are randomised (1:1) to receive either GTN patches or sham patches. A 
randomisation sequence was generated by the trial programmer at the 
Nottingham Stroke Trials Unit (STU) using random-permuted fixed-size blocks 
stratified by ambulance station. Identical looking numbered treatment packs are 
sent in blocks (four treatment packs per block) to each ambulance station. Trial-
trained paramedics only carry one treatment pack at any time. In order to 
minimise selection bias, a participant must be enrolled in the study before the 
treatment pack is opened. Patients and outcome assessors are masked to 
treatment allocation. 
 
Interventions 
The investigational medicinal product is transdermal GTN (5mg daily for 4 days, 
given as Transiderm Nitro ‘5’, Novartis Pharmaceuticals Ltd UK). Although there 
is no matching placebo patch, patients randomised to the control group receive a 
sham patch of similar size to the GTN patch (DuoDERM – a hydrocolloid dressing 
of size 4.4cm x 3.8cm, ConvaTec Ltd UK). The Nottingham University Hospitals 
NHS Trust pharmacy prepare opaque sealed sachets containing either a GTN or 
sham patch, and a gauze dressing. Four of these sachets are contained within a 
larger plastic box (treatment pack) containing a Patient Information Sheet, 
Consent Form and ambulance Case Report Form. Although not identical in 
appearance, both the GTN and DuoDERM patches are unmarked. 
 
The GTN/sham patches are placed on the participant’s shoulders or back and the 
position rotated daily for four days; on days 2 to 4, patches are placed between 
08.00 and 09.00 hours in hospital. The doses of patches are not adjusted during 
treatment. Patches are covered with a gauze dressing to further mask the 
patient to treatment.(17-19) In order to minimise bias that could be introduced 
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through knowledge of what the participant has received, the number of 
unmasked staff is kept to a minimum (paramedic and nursing staff administering 
the patch) and they are asked not to reveal the treatment to colleagues. 
 
If there is an emergency situation where further treatment of the participant is 
dependent on knowledge of the administered treatment, unblinding can be 
performed by review of the patch on the participant’s shoulder or back. Study 
agents are stopped if an alternative diagnosis to stroke is made (e.g. TIA or 
mimic), the patient withdraws consent, for safety reasons, or if unacceptable 
adverse events develop. New prescriptions of non-trial nitrates are avoided, 
where possible, during the treatment period. 
 
Background care 
Treatment is given on top of standard best medical care, including management 
in an acute stroke unit, and treatment with thrombolysis, mechanical 
thrombectomy, hemicraniectomy or other necessary surgery, intensive care, any 
other licensed treatment for acute stroke, and aspirin, as relevant. Clinicians are 
encouraged to comply with national guidelines and actively lower raised BP in 
hospital within the first 6 hours of ICH.(10) In addition, pre-stroke anti-
hypertensive medication is re-started at the discretion of the treating doctor, e.g. 
once the patient is medically stable and can swallow safely or has enteral access. 
Systematic use of long-term oral antithrombotic and lipid lowering agents are 
recommended for secondary prevention in patients with ischaemic stroke, and 
antihypertensive therapy is encouraged, where appropriate, once the 4-day 
treatment period is over. 
 
Data collection and follow-up 
All patients are followed-up daily during the four days of treatment, and then at 
discharge from hospital, and days 90 and 365, unless death occurs earlier (Table 
1, Figure 1). Patients who are unable to complete the four days of treatment as 
per the protocol are still followed at days 90 and 365. Baseline details are 
collected by the recruiting paramedic using data recorded as part of routine 
clinical care; these include information on demography (age, sex), stroke (onset 
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date/time), and physiology (blood pressure, heart rate, oxygen saturation, 
glucose). 
 
On arrival at hospital, further routine clinical details are collected, including 
stroke syndrome,(34), stroke severity (National Institutes of Health Stroke 
Scale, NIHSS (35)), haemodynamics (blood pressure, heart rate). Neuroimaging 
(plain CT or MR scanning, ideally with CT or MR angiography) is performed on 
admission to diagnose stroke type (ischaemic, ICH) or non-stroke lesions. CT 
angiography (if performed as part of routine practice) is used to determine if 
GTN improves collateral blood supply and influences reperfusion. Importantly, 
these hospital admission measures are made on treatment following application 
of the first GTN/sham patch at the stroke scene; hence, it is possible that 
treatment will have altered the diagnosis (e.g. conversion of mild stroke to TIA), 
stroke syndrome and severity, and neuroimaging findings, in hospital. 
 
Blood pressure and heart rate are collected daily, one hour after placement of 
the second, third and fourth treatment patches. A research plain CT (or MR) scan 
is performed on day 2 to allow assessment of the evolution of the infarct and 
symptomatic artery, or haematoma. Intermediate outcome data (e.g. NIHSS, 
adverse events such as headache, hypotension) are collected at day 4 by 
hospital research staff, and the final diagnosis is made at discharge from 
hospital. The primary outcome, modified Rankin Scale (mRS), is determined at 
day 90 with central telephone follow-up by trained staff blinded to treatment 
assignment; additional measures of disability, cognition, mood and quality of life 
are similarly recorded. The same measures are also recorded at day 365 to 
ensure that any findings are maintained long term. 
 
Routine carotid ultrasound examination is performed to identify severe carotid 
stenosis and need for early carotid endarterectomy; such scanning may be 
performed at any time during the hospital admission and is not necessary prior 
to randomisation. Blood pressure is measured using calibrated standard 
semiautomatic equipment available in ambulances and hospitals. 
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All information is entered online over a secure encrypted password/PIN protected 
internet connection (HTTPS) with data validated in real-time.(19) Neuroimaging 
(CT or MR) are interpreted by the local investigator, and then centrally over the 
internet by independent assessors blinded to treatment and using a validated 
structured classification system.(19, 36, 37) Similarly, serious adverse events 
(SAEs) are adjudicated centrally over the internet by independent assessors 
blinded to treatment.(19) 
 
 
Primary Outcome 
The primary outcome is the modified Rankin Scale (mRS).(19, 38-40) mRS is 
determined centrally by telephone by a trained assessor at day 90 (+7 days) 
according to an algorithm.(41) Assessors are masked to treatment assignment 
and baseline clinical characteristics. The primary analysis will compare GTN 
versus sham using ordinal logistic regression, both overall and in pre-specified 
sub-groups. 
 
Secondary outcomes 
Outcomes are assessed at hospital admission; during the four days of 
intervention; then at day 4, discharge from hospital, and days 90 and 365. 
 
Hospital admission: 
• Neurological impairment (NIHSS, /42) 
• Systolic and diastolic blood pressure (mmHg) 
• Systolic blood pressure <185 mmHg, ischaemic stroke (%) 
• Systolic blood pressure <140 mmHg, ICH (%) 
• Heart rate (bpm) 
• Stroke lesion (infarct or haemorrhage) extent on brain scan (CT or MR) 
• Stroke lesion (infarct or haemorrhage) mass effect and swelling 
• Presence of intravascular thrombus (hyperattenuated artery on CT or 
absent flow void/high signal on FLAIR MR) and cerebral arterial patency (CT 
or MR angiography) on relevant brain scanning 
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Use and timing of hyperacute and acute treatments in hospital: 
• Open-label blood pressure lowering (%) 
• Intravenous thrombolysis (%) 
• Intra-arterial therapy / mechanical thrombectomy (%) 
• Hemicraniectomy (%) 
• Surgery for ICH (%) 
• Admission to intensive/critical care unit (%) 
• Required artificial ventilation (%) 
 
At day 2-4: 
• Systolic and diastolic blood pressure, heart rate 
• Neuroimaging: Infarct/haematoma extent, presence of hyper-attenuated 
artery sign (CT) or absent flow void (MR), infarct swelling, secondary 
haemorrhagic transformation of infarct, haematoma expansion 
 
At day 4 (or discharge if sooner): 
• Stroke recurrence (%) 
• Neurological impairment – NIHSS (/42) 
• Neurological deterioration from baseline (NIHSS >=4 points, or >=2 point 
increase in any domain) (%) 
• Infection (pneumonia/chest, urinary tract, other) (%) 
• Feeding status, non-oral (%) 
• Required physiotherapy (%) 
• Required occupational therapy (%) 
• Required speech & language therapy (%) 
 
At discharge/death: 
• Length of stay in hospital (days) 
• Patient disposition (died, institution/in hospital, home) 
 
At days 90 and 365 by telephone (or post): 
• Dependency – mRS >2 (%) 
• Disability/Activities of Daily Living - Barthel Index (BI, /100) 
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• Quality of life - Health Utility Status (HUS, derived from EuroQoL-5D, /1) (42) 
• Quality of life - EQ-Visual Analogue Scale (EQ-VAS) (/100) 
• Cognition - telephone-MMSE (/22) 
• Cognition - Telephone Interview Cognition Scale (TICS, /39) 
• Cognition – verbal fluency (animal naming) (∞) 
• Mood - Zung Depression Scale (ZDS, /102.5) (43) 
• Patient disposition (died, institution/in hospital, home) 
• Stroke recurrence (%) 
 
Safety outcomes 
• Death (%) 
• Serious adverse events, by day 4 (%) 
• Serious adverse events, by day 4 (fatal, non-fatal, none) 
• Headache, by day 4 (%) 
• Infection (pneumonia, chest, urinary tract, other) by day 4 (%) 
• Hypotension, requiring clinical intervention, by day 4 (%) 
• Hypertension, requiring clinical intervention, by day 4 (%) 
 
Investigator-reported serious adverse events are grouped by time of onset 
(during or after treatment), and validated and categorised blindly by 
independent adjudicators. Only fatal SAEs are collected beyond end of treatment 
in view of the existing large safety information available for GTN and other 
organic nitrates, including in acute myocardial infarction and stroke.(19, 44) 
 
Explanatory and mechanistic additional research 
RIGHT-2 aims to study potential mechanisms by which GTN versus sham might 
be beneficial if the primary analysis is statistically positive. These comprise: 
 
Hospital admission (day 1) 
• Plain CT brain – at all sites: 
o Identify stroke type (IS, ICH, non-stroke). 
o Location/length of hyperattenuated artery (CT) or absent flow 
void/increased signal on FLAIR MRI, and visibility and extent of acute 
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ischaemic change or haematoma. 
o Pre-stroke brain health assessed by presence of leukoaraiosis, brain 
atrophy, prior infarct or haemorrhage  
• CT angiography – at some sites: 
o IS – collateral status, and location, length, luminal reduction of any 
occlusion. 
o ICH – active bleeding (spot sign, larger haematoma).(45, 46) 
 
Day 2 
• Plain CT brain – at all sites: 
o IS – Infarct size, mass effect/presence of oedema, location/length of 
hyperdense artery, secondary bleeding.(47) 
o ICH – Haematoma size, presence of intraventricular haemorrhage, 
haematoma expansion, and presence of oedema. 
• Pulse wave analysis - Vascular compliance, some sites: Augmentation index 
(AI), central BP.(16, 17) 
• Transcranial Doppler - Some sites: Middle cerebral artery blood flow velocity, 
cerebral perfusion pressure, zero filling pressure.(16, 17) 
• Blood biomarkers: NO-donation [nitrite/nitrate],(48) tissue damage (S-
100).(49, 50) 
• Genetic blood biomarkers. 
• Hydration status - On BP response: calculated osmolarity 
(2Na+2K+glucose+urea); urea : creatinine ratio; packed cell volume.(51, 52) 
 
Images are curated and adjudicated using a derivative of the MRC IST-3/ENOS 
system, part of the Systematic Image Review System (SIRS-2) web-based 
imaging system from University of Edinburgh (Wardlaw, 
www.neuroimage.co.uk/sirs).(19, 53, 54) 
 
Data Monitoring Committee 
The DMC review unblinded data twice yearly in respect of safety and efficacy, 
and consider the study in the context of other trials of altering BP in stroke. 
Stopping rules are based on the Haybittle-Peto rule as a guide for proof beyond 
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reasonable doubt for: 
 
Hazard 
• Poor outcome (mRS >2) is less frequent in the sham/control group, P<0.01 
(nominal, 2-sided); OR 
• Death is less frequent in the sham/control group, P<0.01 (nominal, 2-sided) 
 
Efficacy 
• Poor outcome (mRS >2) is less frequent in the GTN/active group, P<0.01 
(nominal, 2-sided); AND 
• Death is less frequent in the GTN/active group, P<0.01 (nominal, 2-sided); 
AND 
• Poor outcome (mRS >2) is less frequent in the GTN/active group in ischaemic 
stroke, P<0.01 (nominal, 2-sided); AND 
• Poor outcome (mRS >2) is less frequent in the GTN/active group in 
intracerebral haemorrhage, P<0.05 (nominal, 2-sided). 
The stopping rules for efficacy are designed to persuade practitioners that such a 
simple and inexpensive treatment can significantly reduce poor functional 
outcome, including separately in patients with ischaemic stoke and ICH, and 
reduce death. 
 
The DMC also monitor SAEs and neurological deterioration, and outcomes in 
particular subgroups of patients including those with severe stroke (TACS (34)), 
BP <140 mmHg, those with significant carotid disease (ipsilateral stenosis of the 
internal carotid artery >50%),(55) and those with a final diagnosis of non-
stroke. 
 
Sample size 
The null hypothesis (H0) is that GTN will not shift the mRS in participants with 
ultra-acute stroke. The alternative hypothesis (H1) is that mRS will shift between 
those stroke participants randomised to GTN versus sham. A total sample size of 
850 participants (425 in each arm) is required to detect an ordinal shift in mRS 
with an odds ratio of 0.70 (equivalent to a binary odds ratio of 0.66).(56) This 
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assumes an overall significance level of 5%, and 90% power, and a distribution 
of mRS scores as shown in Table 3 (although the sample size calculation is 
relatively insensitive to variations in the mRS distribution). The calculation also 
assumes 3% loss to follow-up, a non-stroke diagnosis (stroke mimic and TIA) of 
20%,(18) and reduction for baseline co-variate adjustment of 20%.(57) If only 
650 participants are recruited, there will be 82% power to detect this odds ratio 
using the same assumptions above. Whilst one formal interim analysis is 
planned, no adjustment has been made to the sample size given the pre-
specified high level of significance required to stop the trial. 
 
Analysis populations 
RIGHT-2 will follow the intention-to-treat principle, i.e. analysis is based on the 
initial treatment assignment and not on the treatment received. Additionally, the 
primary efficacy analysis will be performed in patients with a stroke, or a stroke 
and TIA, since there is no expectation that GTN will alter outcomes in patients 
presenting with a mimic. Finally, a per protocol analysis may be performed for 
hypothesis-generation if the primary analysis shows a significant treatment 
effect. 
 
Statistical analyses 
The distribution of mRS at day 90 between GTN and sham groups will be 
analysed using ordinal logistic regression with adjustment for age, sex, pre-
morbid mRS, FAST, pre-treatment systolic BP, index event (ICH, ischaemic 
stroke, TIA, mimic) and time to treatment. The effect of GTN on mRS will be 
studied in pre-specified subgroups comprising those based on premorbid or 
ambulance/pre-randomisation data, and on post-treatment data collected at 
admission to hospital. This distinction is necessary since GTN may alter 
information collected at admission to hospital such as diagnosis (e.g. stroke to 
TIA), stroke syndrome and severity, and neuroimaging findings. 
 
Other outcomes will be analysed using binary logistic regression for dichotomised 
measures (e.g. serious adverse events), Cox proportional hazards regression 
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(e.g. time to death), or multiple linear regression (e.g. NIHSS, MMSE, HUS, 
ZDS), with presentation of 95% confidence intervals and two-sided p-values. 
 
Study organisation and funding 
RIGHT-2 is an independent academic trial performed by a UK collaborative 
group. The study is supervised by a Trial Steering Committee and receives 
advice from an International Advisory Committee. The trial is run day-to-day by 
a Trial Management Committee based at the Coordinating Centre in Nottingham. 
Approximately 7 ambulance services across the UK will recruit, initiate treatment 
and then transport patients to ~40 acute hospitals with a stroke service. The 
image data are managed by researchers at the University of Edinburgh, via 
databases for image management and transfer of results of image reads linked 
to the University of Nottingham. Independent and blinded Adjudicators classify 
serious adverse events for a separate and independent Data Monitoring 
Committee. The trial is funded by the British Heart Foundation; the University of 
Nottingham is the sponsor. 
 
Publication and data sharing 
In addition to this description of the RIGHT-2 protocol, subsequent publications 
will report the statistical analysis plan (prior to data-lock at trial conclusion), a 
complete description of baseline data, and the main results. This approach 
follows that used in the ENOS trial.(58-60) Subsequent publications will focus on 
the effect of GTN on potential mechanisms of action, and factors involved in 
delivering a large multicentre paramedic-delivered ambulance-based ultra-acute 
stroke trial. 
 
In the future, data from RIGHT-2 will be added to the Cochrane Collaboration 
review of NO donors in stroke,(61) and integrated into individual patient data 
meta-analyses of nitric oxide donors,(31) and blood pressure lowering, for acute 
stroke (the latter through the ‘Blood pressure in Acute Stroke Collaboration’, 
BASC), and the ‘Virtual International Stroke Trials Archive’ (VISTA).(62) 
Ultimately, a subset of the data will be made available over the web, as with the 
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International Stroke Trial.(63) Similarly, anonymised neuroimaging data will be 
published.(54) 
 
Summary and conclusions 
RIGHT-2 is addressing the safety and efficacy of ultra-acute administration of 
GTN in patients with stroke. The trial is also examining the feasibility of 
performing a large multicentre stroke trial embedded within the ambulance 
service of the UK. The large sample size of 850 patients (exceeding the size of 
hemicraniectomy and thrombectomy trials, and comparable in size to alteplase 
trials such as ECASS-3 (64)) means that a moderate-high clinical effect can be 
detectable with high statistical power (90%). A positive trial could be 
implemented easily because of the pragmatic inclusion criteria and collection of 
safety data from non-stroke participants. As such, transdermal GTN could be 
introduced rapidly into pre-hospital clinical practice around the world since it is 
readily available, easy to administer, and inexpensive (£2 per patient, equivalent 
to €2.5/$3). Successful delivery of the trial, whatever the result for GTN, would 
also support FAST-Mag (29) in demonstrating that large multicentre pre-hospital 
based trials are feasible in ultra-acute stroke. 
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TABLE 1. Schedule of procedures and evaluations 
 
Timing Baseline 
Day 1 
+15 
min 
Day 
1 
Day 
2 
Day 
3 
Day 
4±1 
Discharge Day 
90±7 
Day 
365±7 
Environment Amb Amb Hosp Hosp Hosp Hosp Hosp Tel/post Tel/post 
Paramedic: Consent/proxy-consent for main trial ü         
Enrolment ü         
Baseline assessment: FAST, BP/HR, ECG ü         
Administer GTN/sham + gauze dressing ü   ü ü ü    
Blood pressure & heart rate   ü ü ü* ü* ü*    
Paramedic-hospital handover   ü       
Consent if patient lacks capacity in ambulance ~   < = = = >   
Impairment / deterioration (NIHSS/GCS)   ü ü ü ü    
CT brain, plain †   ü ü      
CT angiography - if routine †   ü       
Haematology/chemistry/ECG - routine   ü       
All SAEs including fatal SAEs   ü ü ü ü ü**   
Fatal SAEs       ü ü ü 
Recurrent stroke   ü ü ü ü ü ü ü 
Tolerability/side effects   ü ü ü ü    
Plain CT scan - routine if post rt-PA †    ü      
Additional clinical neuroimaging   ü ü ü ü ü   
Consent for additional research (where appropriate)   ü ü ü     
24 hour ambulatory blood pressure monitoring ‡   < = >     
Blood biomarkers (e.g. S-100, NOx, P-selectin) ‡   < = >     
Genetics: EDTA sample ‡   < = >     
Pulse wave analysis ‡   < =* >     
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Transcranial Doppler ‡   < =* >     
Consent if patient regains capacity   < = = = >   
Disposition (home/institution/home)       ü ü ü 
Dependency: modified Rankin Scale        ü ü 
Disability: Barthel Index        ü ü 
Cognition: MMSE, TICS        ü ü 
Quality of Life: EQ-5D, EQ-VAS        ü ü 
Mood: Zung Depression Scale        ü ü 
*1-2 hours after administration of GTN/sham patch; **If discharge before Day 4; Routine care in italics. Amb: Ambulance; BP: Blood pressure; FAST: Face, Arm, Speech, Time test; 
GCS: Glasgow Coma Scale; Hosp: Hospital; HR: heart rate; IMP: Investigational Medicinal Product; MMSE: Mini-Mental State Examination; NIHSS: National Institutes of Health Stroke 
Scale; Tel: Telephone (done by central telephone questionnaire masked to treatment assignment); TICS: Telephone Interview of Cognition Status.  † Imaging sent as ‘volume data’‡ 
Separate consent to be obtained in-hospital.  08.00 Time (+/- 2 hour) for patch administration or measurement ~Only for participants whose baseline consent was by proxy (can be 
anytime during hospital stay). 
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TABLE 2. Comparison and contrast of inclusion and exclusion criteria for RIGHT-2 (uses 
Face, Arm, Speech, Time test, FAST) versus FAST-MAG (used modified Los Angeles 
Prehospital Stroke Screen, mLAPSS) 
 
Criteria RIGHT-2 mLAPSS/FAST-MAG (29, 65) 
Age 18- 40-95 
History of seizure 
absent 
Witnessed at/after 
stroke 
Ever 
Symptom duration <4 hours <2 hours 
Disability/dependency Not in nursing home Not wheelchair bound or 
bedridden 
Blood glucose (mmol/L) 2.5- 3.3-22.2 
Face weak/droop Yes Yes 
Arm weak/drift Yes Yes 
Speech Yes - 
FAST † 2 or 3 - 
Grip weak/none - Yes 
Glasgow coma scale 8-15 - 
 
† FAST (66) = facial weakness + arm weakness + speech abnormality 
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TABLE 3. Distribution of modified Rankin Scale (mRS) in pre-hospital stroke trials with 
aggregation of rates across treatment groups. The sample size calculation for RIGHT-2 
assumes the mRS distribution seen in the RIGHT pilot trial (highlighted in bold).(18) 
However, the calculation is relatively immune to the actual distribution; the final column 
shows the estimated sample size based on the different mRS distributions (and 
assuming power = 90%, significance = 5% and odds ratio = 0.70). 
 
 
 
 
 
 
  
Modified Rankin Scale (%) N 0 1 2 3 4 5 Dead N 
RIGHT (18) 41 2 17 20 15 10 12 24 821 
ENOS-early (20) 273 10 16 18 19 18 6 14 815 
FAST-Mag pilot (21) 20 25 15 20 5 0 0 35 853 
FAST-Mag (29) 1700 21 15 16 12 10 10 15 813 
Mobile stroke unit (22, 23) 100 16 17 8 12 10 11 8 805 
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FIGURE 1. Meta-analysis of randomised controlled trials of glyceryl trinitrate involving 
patients treated within 6 hours of randomisation.(18-20) 
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FIGURE 2. Flow of patients through trial. 
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FIGURE 3. Consent algorithm 
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Researcher	assesses	participant	for	
capacity 
Participant	has	
capacity 
Participant	lacks	
capacity 
Researcher	further	
explains	trial	and	
answers	any	
further	questions.	
	
Where	
appropriate,	
researcher	asks	for	
written	informed	
consent	for	
additional	
Researcher	further	
explains	trial	**to	
relatives,	answers	any	
further	questions	and	
obtains	proxy	consent	for	
continuation	in	study. 
Where	appropriate,	
researcher	asks	for	
written	informed	consent	
for	additional	research	
from	relative/	friend. If	
not	present,	the	
participant	cannot	take	
HO
SP
IT
AL
 
DA
Y	
ENROLMENT	AND	TREATMENT 
Consent	reconfirmed	verbally*** 
Researcher	further	
explains	trial**,	
answers	any	
questions	and	obtains	
written	consent	for	
continuation	in	study.	
	
Where	appropriate,	
researcher	asks	for	
written	informed	
consent	for	additional	
research. 
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* Using short information sheet/consent form 
** Using long information sheet and consent to continue form 
*** If participant contacted by post, return of questionnaires will represent consent to 
continue participation in the study 
 
 
 
